Alzheimer's disease, China and Kisunla

Eli Lilly's Alzheimer's treatment approved in China (Dec. 17)
(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi) (Reuters) -China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's,
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi (lecanemab), which was cleared by the NMPA in January.
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion),
Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a
Eli Lilly Alzheimer's therapy approved in China
Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.
Global Health Advancements: Eli Lilly's Alzheimer's Treatment Gains Ground
The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in China, Merck's deal with Hansoh for a new obesity drug, impending HIV medication availability,
China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment
Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt,

MN patients getting new treatment

Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
BioSpace3d
Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
Business Insider1d
Eli Lilly’s Kisunla approved in China for Alzheimer’s Disease treatment
The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic Alzheimer’s ...
Grasping for hope: The heartbreaking journey through Alzheimer’s drug trials
For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...